BNTX (BioNTech SE) Tariff Resilience Score: 7/10 (As of Jul. 07, 2026)


BNTX BioNTech SE BNTX
62 GF Score
Price $93.93
GF Value $87.60
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioNTech SE Tariff Resilience Score?

BioNTech SE BNTX -3.71% 62 Tariff Resilience Score is 7 as of Jul. 07, 2026. GuruFocus rates BNTX with a GF Score™ of 62/100 and a GF Value™ of $87.60 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,368 Biotechnology companies, BioNTech SE ranks better than 90.35% on this metric.

BioNTech SE has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

BioNTech SE has BioNTech SE, a biotech firm, has moderate tariff exposure. While its products are globally distributed, the industry benefits from some exemptions. The company's focus on high-value pharmaceuticals and strong pricing power provides resilience against tariff-induced cost increases.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes BioNTech SE might have Highly Resilient.

BioNTech SE  (NAS:BNTX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

BioNTech SE Tariff Resilience Score Related Terms

BNTX vs INCY, INSM, ROIV: Tariff Resilience Score Comparison

For the Biotechnology subindustry, BioNTech SE's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNTech SE Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioNTech SE's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where BioNTech SE's Tariff Resilience Score falls into.


BNTX
62GF Score
BioNTech SE BNTX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
BioNTech SE (BNTX) has a Tariff Resilience Score of 7 as of Jul. 07, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, BioNTech SE ranks #132 out of 1368 companies in the Biotechnology industry, placing it in the top 9.6%.
Is BioNTech SE's Tariff Resilience Score too high?
BioNTech SE's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. BioNTech SE's value of 7 is 75% above this industry median. Based on the distribution chart, BioNTech SE ranks #132 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioNTech SE has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Tariff Resilience Score compare to INCY and INSM?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #132 out of 1368 companies for Tariff Resilience Score. This places BioNTech SE in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. BioNTech SE's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNTech SE's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNTech SE's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BNTX) is currently considered Fairly Valued. The stock's GF Value™ is $87.60, compared to a current price of $93.93 — trading 7.2% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. BioNTech SE's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For BioNTech SE (BNTX), the current Tariff Resilience Score is 7 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioNTech SE (BNTX) Overvalued in 2026?

Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued. The current stock price of $93.93 is trading 7.2% above its estimated GF Value™ of $87.60. GuruFocus considers BioNTech SE to be Fairly Valued.

Key valuation signals for BNTX:

  • Tariff Resilience Score: 7
  • GF Value™: $87.60 vs. price of $93.93 (7.2% above fair value)
  • GF Score™: 62/100 with 5 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1368)

No single metric tells the full story. See the BNTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioNTech SE Business Description

Address An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
62GF Score

Get the complete analysis for BNTX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$93.93
Price
$87.60
GF Value